Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IOSTB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
PLB-002
|
|||||
| Synonyms |
PLB-002; PLB-002
Click to Show/Hide
|
|||||
| Organization |
ProLyn Biotech (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
PLB-002-ab7
|
Antibody Info | ||||
| Antigen Name |
Claudin-6 (CLDN6)
|
Antigen Info | ||||
| Payload Name |
Eribulin
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Fallopian tube cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
||||||||
| Peritoneal cancer |
1 Trials
|
||||||||
| Testicular cancer |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|